{"nctId":"NCT00118898","briefTitle":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","startDateStruct":{"date":"2005-09"},"conditions":["HIV Infections"],"count":1864,"armGroups":[{"label":"EFV, FTC/TDF, and placebo ABC/3TC","type":"EXPERIMENTAL","interventionNames":["Drug: Efavirenz","Drug: Emtricitabine/Tenofovir disoproxil fumarate","Drug: Abacavir/Lamivudine placebo"]},{"label":"EFV, ABC/3TC and placebo FTC/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: Abacavir/Lamivudine","Drug: Efavirenz","Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo"]},{"label":"RTV-boosted ATV, FTC/TDF, and placebo ABC/3TC","type":"EXPERIMENTAL","interventionNames":["Drug: Atazanavir","Drug: Emtricitabine/Tenofovir disoproxil fumarate","Drug: Ritonavir","Drug: Abacavir/Lamivudine placebo"]},{"label":"RTV-boosted ATV, ABC/3TC, and placebo FTC/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: Abacavir/Lamivudine","Drug: Atazanavir","Drug: Ritonavir","Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo"]}],"interventions":[{"name":"Abacavir/Lamivudine","otherNames":["ABC/3TC"]},{"name":"Atazanavir","otherNames":["ATV"]},{"name":"Efavirenz","otherNames":["EFV"]},{"name":"Emtricitabine/Tenofovir disoproxil fumarate","otherNames":["FTC/TDF"]},{"name":"Ritonavir","otherNames":["RTV"]},{"name":"Abacavir/Lamivudine placebo","otherNames":["ABC/3TC placebo"]},{"name":"Emtricitabine/Tenofovir disoproxil fumarate placebo","otherNames":["FTC/TDF placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-infected. A resistance assay must be obtained if the participant has evidence of recent infection. More information on this criterion can be found in the protocol.\n* Antiretroviral naive, defined as 7 days or less of ARV treatment at any time prior to study entry. Participants who have received ARVs as part of postexposure prophylaxis or who have received an investigational drug that was not an NRTI, NNRTI, or PI are eligible for this study.\n* HIV viral load greater than 1,000 copies/ml within 90 days prior to study entry\n* Certain laboratory values obtained within 30 days prior to study entry. More information on this criterion can be found in the protocol\n* Willing to use acceptable forms of contraception\n* Parent or guardian able and willing to provide written informed consent, if applicable\n* Hepatitis B surface antigen (HBsAg) negative at study entry\n\nExclusion Criteria:\n\n* Immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry. Individuals receiving either stable physiologic glucocorticoid doses, corticosteroids for acute therapy for pneumocystis pneumonia, or a short course (2 weeks or less) of pharmacologic glucocorticoid therapy will not be excluded.\n* Known allergy/sensitivity to study drugs or their formulations\n* Active alcohol or drug use that, in the opinion of the investigator, would interfere with adherence to study requirements\n* Serious illness requiring systemic treatment or hospitalization. Patients who have completed therapy or are clinically stable on therapy for at least 7 days prior to study entry are not excluded.\n* Known clinically relevant cardiac conduction system disease\n* Requirement for any current medications that are prohibited with any study treatment.\n* Evidence of any major drug resistance-associated mutation on any genotype or evidence of significant resistance on any phenotype performed at any time prior to study entry.\n* Current imprisonment or involuntary incarceration for psychiatric or physical (e.g., infectious disease) illness\n* Breastfeeding. Women who become pregnant during the study will be unblinded and required to permanently discontinue their study regimens.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time From Randomization to Virologic Failure","description":"Blood samples for determining virologic failure were obtained at visit weeks 16 and 24 , and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level \\>= 1000 copies/mL at or after 16 weeks after randomization and before 24 weeks, or \\>=200 copies/mL at or after 24 weeks. The 5th percentile for time to virologic failure is the time (in weeks) at which 5% of the participants have experienced virologic failure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"84","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Amount of Study Follow-up","description":"Participants were to be followed for 96 weeks after the last enrollment. Accrual was expected to take 96 weeks, thus the planned follow-up time was 96 to 192 weeks, dependent on when in the study the participant enrolled. This outcome summarizes that total amount of actual follow-up in weeks from randomization to last contact.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141.4","spread":null},{"groupId":"OG001","value":"133.3","spread":null},{"groupId":"OG002","value":"141.6","spread":null},{"groupId":"OG003","value":"137.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Virologic Failure","description":"Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level \\>= 1000 copies/mL at or after 16 weeks and before 24 weeks or \\>=200 copies/mL at or after 24 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Treatment Dispensation to Regimen Failure (First Occurrence of Virologic Failure or Treatment Modification)","description":"Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level \\>= 1000 copies/mL at or after 16 weeks and before 24 weeks or \\>=200 copies/mL at or after 24 weeks. Treatment modification was defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"84","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"415","spread":null},{"groupId":"OG001","value":"400","spread":null},{"groupId":"OG002","value":"416","spread":null},{"groupId":"OG003","value":"411","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":null},{"groupId":"OG001","value":"346","spread":null},{"groupId":"OG002","value":"348","spread":null},{"groupId":"OG003","value":"322","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"361","spread":null},{"groupId":"OG002","value":"384","spread":null},{"groupId":"OG003","value":"374","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"345","spread":null},{"groupId":"OG001","value":"328","spread":null},{"groupId":"OG002","value":"345","spread":null},{"groupId":"OG003","value":"317","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HIV-1 RNA Levels Less Than 200 Copies/mL","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"415","spread":null},{"groupId":"OG001","value":"400","spread":null},{"groupId":"OG002","value":"416","spread":null},{"groupId":"OG003","value":"411","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"398","spread":null},{"groupId":"OG001","value":"377","spread":null},{"groupId":"OG002","value":"391","spread":null},{"groupId":"OG003","value":"372","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"361","spread":null},{"groupId":"OG002","value":"384","spread":null},{"groupId":"OG003","value":"374","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"362","spread":null},{"groupId":"OG001","value":"342","spread":null},{"groupId":"OG002","value":"368","spread":null},{"groupId":"OG003","value":"346","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in CD4 Count (Cells/mm3) From Baseline","description":"Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (mean of pre-entry and entry values).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"188","spread":null},{"groupId":"OG002","value":"175","spread":null},{"groupId":"OG003","value":"177.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"220.5","spread":null},{"groupId":"OG001","value":"250.5","spread":null},{"groupId":"OG002","value":"251.5","spread":null},{"groupId":"OG003","value":"250.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Failure and Emergence of Major Resistance","description":"Emergence of resistant virus was assessed by genotypic testing performed at Stanford University for all participants who met criteria for virologic failure and retrospectively on baseline samples from these participants. Major mutations were defined by International AIDS Society-United States of America (2008), as well as T69D, L74I, G190C/E/Q/T/V for reverse transcriptase and L24I, F53L, I54V/A/T/S, G73C/S/T/A, N88D for protease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Certain Targeted Clinical Events, Including Death, AIDS-defining Illness, and HIV-1 Related Events.","description":"AIDS-defining illnesses were defined per CDC category C definition. HIV-1 related events were defined per CDC category B definition. Events underwent study chair review for classification. See link below for more details.\n\nhttp://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Total Cholesterol Level From Baseline","description":"Only fasting results are included. The protocol did not require that samples be collected fasting.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting High-density Lipoprotein (HDL) Cholesterol Level From Baseline","description":"Only fasting results are included. The protocol did not require that samples be collected fasting.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Level From Baseline","description":"Only fasting results are included. The protocol did not require that samples be collected fasting.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]}]},{"type":"PRIMARY","title":"Time From Treatment Dispensation to a Grade 3/4 Safety Event","description":"Grade 3/4 safety event is defined as a grade 3 or 4 sign, symptom, or laboratory abnormality that is at least one grade higher than at baseline, total bilirubin and creatine kinase (CPK) were excluded. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"3.0","spread":null},{"groupId":"OG003","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"8.1","spread":null},{"groupId":"OG003","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null},{"groupId":"OG001","value":"16.0","spread":null},{"groupId":"OG002","value":"81.4","spread":null},{"groupId":"OG003","value":"44.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Probability of Not Experiencing Virologic Failure","description":"Kaplan-Meier estimate of the cumulative survival probability at week 48 and 96. Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level \\>= 1000 copies/mL at or after 16 weeks and before 24 weeks or \\>=200 copies/mL at or after 24 weeks.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"92","spread":null},{"groupId":"OG003","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"89","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]}]},{"type":"PRIMARY","title":"Time From Treatment Dispensation to Treatment Modification","description":"Treatment modification is defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"1.4","spread":null},{"groupId":"OG002","value":"7.9","spread":null},{"groupId":"OG003","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"24.9","spread":null},{"groupId":"OG003","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7","spread":null},{"groupId":"OG001","value":"27.4","spread":null},{"groupId":"OG002","value":"108.9","spread":null},{"groupId":"OG003","value":"43.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With a Grade 3/4 Safety Event","description":"Grade 3/4 safety event is defined as a grade 3 or 4 sign, symptom, or laboratory abnormality that is at least one grade higher than at baseline, total bilirubin and creatine kinase (CPK) were excluded. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables. As-treated analysis censored at 1st modification of initially assigned regimen, participants who never started treatment were excluded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"182","spread":null},{"groupId":"OG002","value":"137","spread":null},{"groupId":"OG003","value":"156","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Probability of Not Experiencing a Grade 3/4 Safety Event","description":"Kaplan-Meier estimate of the cumulative survival probability at week 48 and 96. Grade 3/4 safety event is defined as a grade 3 or 4 sign, symptom, or laboratory abnormality that is at least one grade higher than at baseline, total bilirubin and creatine kinase (CPK) were excluded. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables. As-treated analysis censored at 1st modification of initially assigned regimen, participants who never started treatment were excluded.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"66","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Treatment Modification","description":"Treatment modification is defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"239","spread":null},{"groupId":"OG002","value":"138","spread":null},{"groupId":"OG003","value":"216","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Probability of Not Experiencing Treatment Modification","description":"Kaplan-Meier estimate of the cumulative survival probability at week 48 and 96. Treatment modification is defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"77","spread":null},{"groupId":"OG003","value":"62","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Regimen Failure","description":"Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level \\>= 1000 copies/mL at or after 16 weeks and before 24 weeks or \\>=200 copies/mL at or after 24 weeks. Treatment modification was defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"246","spread":null},{"groupId":"OG002","value":"157","spread":null},{"groupId":"OG003","value":"233","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Probability of Not Experiencing Regimen Failure","description":"Kaplan-Meier estimate of the cumulative survival probability at week 48 and 96. Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level \\>= 1000 copies/mL at or after 16 weeks and before 24 weeks or \\>=200 copies/mL at or after 24 weeks. Treatment modification was defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Triglyceride Level From Baseline","description":"Only fasting results are included. The protocol did not require that samples be collected fasting.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":48,"n":461},"commonTop":["Blood cholesterol abnormal","Blood bilirubin increased","Low density lipoprotein abnormal","Blood glucose abnormal","Neutrophil count decreased"]}}}